Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Boronic Acids
  • Drug Resistance, Neoplasm
  • Multiple Myeloma
  • Neoplasm Recurrence, Local
  • Pyrazines

abstract

  • Retreatment with or continuation of bortezomib +/- dexamethasone beyond 6 months was safe, and toxicities were manageable, in patients with relapsed and/or refractory myeloma.

publication date

  • November 15, 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.21427

PubMed ID

  • 16206291

Additional Document Info

start page

  • 2141

end page

  • 8

volume

  • 104

number

  • 10